期刊文献+

地西他滨10天方案治疗初治老年急性髓系白血病的疗效及安全性初步探讨 被引量:5

A pilot study of ten-day decitabine regimen as initial therapy for newly diagnosed elderly patients with acute myeloid leukemia
原文传递
导出
摘要 老年急性髓系白血病(AML)患者在白血病发病前常有前驱血液病史,此外,老年AML患者因骨髓生理性衰竭正常干细胞数量较少,化疗致骨髓抑制后再生恢复能力减弱,抑制期相关并发症发生率增加;一般来说,随着年龄的增大患者合并疾病的概率也随之增高,治疗相关不良反应增加。
出处 《中华血液学杂志》 CAS CSCD 北大核心 2016年第11期993-995,共3页 Chinese Journal of Hematology
基金 国家自然科学基金(81470297、81370611) 国家科技支撑计划(2014BAI09B13) 协和学者与创新团队发展计划
  • 相关文献

参考文献2

二级参考文献14

  • 1Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment [J~. J Clin Oncol, 2011,29 (33):4417- 4423.
  • 2Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose Cytarabine and Hydroxyurea with or without all-trans retinoie acid for acute mycloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment[J]+ Cancer, 2007,109(6) : 1114-1124.
  • 3L6enberg B, Ossenkoppele D J, van Putten W, et al. High-dose Daunorubiein in older patients with acute myeloid leukemia [J]. N Engl J Med, 2009, 361 (13) : 1235-1248.
  • 4Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia[J]. J Clin Oncol, 2010,28 (4):562- 569.
  • 5Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multieenter, randomized, open-label, phase m trial of Deeitabine versus patient choice, with physician advice, of either supportive care or low-dose Cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia [J~. J Clin Oncol, 2012,30(12) : 26/0-2677.
  • 6Faded A, Ravandi F, Huang X, et al. Clofarabine plus low- dose Cytarabine followed by Clofarabine plus low-dose Cytarabine alternating with Decitabine in AML frontline therapyof older patients [ J ]. Cancer, 2012,118 (18) : 4471-4477.
  • 7Pollyea DA, Kohrt HE, Gallegos L, et al. Safety, efficacy and biological predictors of response to sequential Azacitidine and Lenalidomide for elderly patients with acute myeloid leukemia [J]. Leukemia, 2012,26(5):893-901.
  • 8Gardin C, Chevret S, Pautas C, et al. Superior long-term outeome with Idarubicin compared with high-dose Daunorubicin in patients with acute myeloid leukemia age 50 years and older [J]. J Clin Oncol, 2013,31(3):321-327.
  • 9Hasserjian RP, Campigottu F, Klcpeis V, et al. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with /> 30% blasts in older adults: A Bone Marrow Pathology Group Study[J]. Am J Hematol, 2014,89(11) :e193-e199.
  • 10Pleyer L, Burgstaller S, Girschikofsky M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: Results from the Austrian Azacitidine Registry of the AGMT- Study Group[J]. Ann Hematol, 2014,93(11 ) : 1825-1838.

共引文献20

同被引文献64

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部